BRIEF—Relief and NRx announce tentative settlement

Relief Therapeutics and NRx Pharmaceuticals have agreed to a tentative settlement of their pending litigation.

The litigation came as a result of a dispute between the two companies following a collaboration agreement to develop aviptadil. Relief’s lawsuit claimed rights to the drug, which NRx continued to fund and develop after Relief ceased funding the project.

The parties have agreed to work collaboratively to finalize the settlement within the next 30 days. Further, the parties have agreed to stay the litigation for an additional 60 days to allow for the negotiation and execution of the definitive settlement agreement and related terms.

Terms of the settlement will be reported following execution of the definitive settlement documents, but any settlement may result in a re-allocation of the development rights and licensing arrangements for aviptadil.